Elongator (ELP) complexes can promote MCL-1 expression through tRNA modification, resulting in triple-negative breast cancer resistance to erlotinib.307 Other mechanisms, such as gene hypomethylation, gene rearrangements, and silencing mutations in noncoding RNAs that regulate BCL-2, can also upregulate BCL-2.303 However, some of these factors have not yet been demonstrated to be associated with TKI resistance. The gene discussed is BCL2; the disease is triple-negative breast carcinoma.